In-vivo Imaging Market Trends

Growth Drivers

• Rise in theranostics: This refers to radionuclide therapy and most preferably radiopharmaceuticals comprising radionuclides for imaging therapy, thereby positively uplifting the in-vivo imaging market. As per an article published by NLM in July 2023, the Phase III ALSYMPCA trial displayed that radium 223–dichloride (223RaCl2) is effectively tolerated and optimized for survival within 14.9 months for aiding arm, and further denoting a 30% risk reduction, thereby suitable for uplifting the overall market across different nations through theranostics implementation.

• 3D bioprinting integration: This is successfully revolutionizing the overall healthcare system by developing patient-specific organs, tissues, and implants, which are readily contributing to the in-vivo imaging market’s growth. As per the December 2022 NLM article, with a surge in innovation, the 3D bioprinting market has been valued at USD 1.7 billion over the past 4 years, which is further projected to increase to USD 1.9 billion by the end of 2025, along with a growth rate of 15.8%, thereby suitable for bolstering the market’s exposure internationally. This upliftment is subject to increased R&D investments, technological progression, and private funding trends.

• Regulatory pressure on preclinical testing: This driver is suitable for the in-vivo imaging market’s growth, owing to the efficacy and safety of the latest drugs and medical treatments within laboratories. In this regard, the February 2022 NLM article denoted that drug development and delivery have emerged to be a lengthy and expensive process that takes more than 10 to 15 years, along with an average expense of over USD 1 to USD 2 billion for each newly introduced drug. Therefore, this is an essential part of prenatal testing, which in turn is extremely suitable for the overall market development.

2021 Female Infertility Cases Driving the In-Vivo Imaging Market Demand

Source: NLM, May 2025

Type 1 and 2 Diabetes 2021 Prevalence Among Adults Uplifting the In-Vivo Imaging Market

Source: OECD 2023

Challenges

• Heterogeneous and strict administrative approval processes: The most common gap in the in-vivo imaging market is effectively navigating a complicated international labyrinth of administrative demands. Agencies, such as EMA, FDA, and PDMA, have readily demanded unique and extensive clinical data packages to prove the efficiency and safety. This heterogeneity has pressured manufacturers to operate expensive and parallel submission initiatives, which drastically enhanced R&D and time-to-market expenditure, thereby causing a hindrance in the market’s development internationally.

• Reimbursement and government-based pricing caps: The aspect of profit margins is critically constrained by government health bodies that have mandated affordable analyses. Agencies, including NICE in the UK and IQWiG in Germany, frequently benchmark the latest imaging technologies against existing reforms, which results in the demand for significant price concessions for ensuring improvements. Besides, reimbursement rates are usually set low, particularly for novel-based applications, which has negatively impacted the in-vivo imaging market globally.